Company Profile

Naurex Inc (AKA: Nyxis Neurotherapeutics Inc.)
Profile last edited on: 9/15/22      CAGE: 47FQ0      UEI:

Business Identifier: Novel therapeutics for depression and other CNS disorders
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1801 Maple Avenue #4300
Evanston, IL 60201
   (847) 871-0377
Location: Single
Congr. District: 09
County: Cook

Public Profile

Acquired by Allergan Inc in 2015, Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. As of August 2015, Naurex, Inc. has operated as a subsidiary of Allergan plc. Coincident with the aquisition, Naurex Inc. spun off its discovery platform for N-methyl-D-aspartic acid (NMDA) modulators to include the new company owning Naurex's medical chemistry and related IP.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 1 NIH $197,633
Project Title: Mitigating Taxol-Induced Neuropathy Through Modulation of the Nmda Receptor

Key People / Management

  Norbert G Riedel -- Chief Executive Officer, President And Director

  Jeff Burgdorf

  Joseph Moskal -- Founder and CSO

  James E Schulz